Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Stoke Therapeutics (STOK) Assets Average (2022 - 2025)

Historic Assets Average for Stoke Therapeutics (STOK) over the last 4 years, with Q3 2025 value amounting to $372.4 million.

  • Stoke Therapeutics' Assets Average rose 2390.65% to $372.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $372.4 million, marking a year-over-year increase of 2390.65%. This contributed to the annual value of $249.9 million for FY2024, which is 319.73% up from last year.
  • According to the latest figures from Q3 2025, Stoke Therapeutics' Assets Average is $372.4 million, which was up 2390.65% from $395.7 million recorded in Q2 2025.
  • Stoke Therapeutics' 5-year Assets Average high stood at $395.7 million for Q2 2025, and its period low was $216.8 million during Q1 2024.
  • Moreover, its 4-year median value for Assets Average was $275.9 million (2023), whereas its average is $289.2 million.
  • Its Assets Average has fluctuated over the past 5 years, first crashed by 1939.88% in 2024, then surged by 5649.49% in 2025.
  • Over the past 4 years, Stoke Therapeutics' Assets Average (Quarter) stood at $266.8 million in 2022, then decreased by 12.27% to $234.1 million in 2023, then increased by 20.64% to $282.4 million in 2024, then skyrocketed by 31.85% to $372.4 million in 2025.
  • Its Assets Average stands at $372.4 million for Q3 2025, versus $395.7 million for Q2 2025 and $339.2 million for Q1 2025.